Medicare's National Coverage Determinations in Diagnostic Radiology: Examining Evidence and Setting Limits

被引:6
|
作者
Otero, Hansel Javier [1 ,2 ]
Chambers, James D. [2 ]
Bresnahan, Brian W. [3 ]
Kamae, Maki S. [2 ]
Yucel, Kent E. [1 ]
Neumann, Peter J. [2 ]
机构
[1] Inst Clin Res & Hlth Policy Studies, Dept Radiol, Boston, MA 02111 USA
[2] Inst Clin Res & Hlth Policy Studies, Ctr Evaluat Value & Risk Hlth, Boston, MA 02111 USA
[3] Univ Washington, Sch Med, Dept Radiol, Seattle, WA 98195 USA
关键词
Medicare; evidence based medicine; diagnostic imaging; CANCER;
D O I
10.1016/j.acra.2012.05.005
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Objective: To systematically review and summarize the Center for Medicare and Medicaid Services (CMS) national coverage determination (NCDs) pertaining diagnostic imaging technologies from 1999 through 2010. Methods: All NCDs pertaining to diagnostic imaging were identified from the Tufts Medical Center NCD database. The variables under study included the quality of the clinical evidence and the final coverage determination. The types of restrictions were categorized. We also categorized the final decisions as "positive coverage" or "no positive/no change in coverage" and assessed the correlation between positive coverage and other variables using Fisher exact test. Results: Twenty-two of 152 (15%) NCDs pertained to diagnostic imaging technologies. The supporting evidence was judge to be good, fair, and poor in 5, 6, and 11 cases, respectively. Eleven technologies (50%) were covered with conditions, four (18%) deferred the coverage decision to local level, and two (9%) were completely not covered. In five instances there was no change to the prior coverage status. Of the 11 decisions resulting in positive coverage, 8 (73%) restricted use to specific population subgroups, 5 (46%) applied restrictions related to treatment, 4 were covered with evidence development, and 2 were restricted to care in specific settings. A significantly higher rate of positive coverage decisions was achieved if the available evidence was good (100% 5/5) or fair (83% 5/6) compared to technologies with poor evidence (10% 1/10) (P < .01). Conclusion: CMS has demonstrated a propensity to limit the use of advanced diagnostic imaging to scenarios in which appropriateness is supported by adequate evidence of clinical utility and improved outcomes with the quality of evidence being a significant factor on final decisions. Understanding the need for high-quality evidence and the types of limitations placed on coverage allows for appropriate planning for the incorporation of diagnostic imaging technologies into clinical practice.
引用
收藏
页码:1060 / 1065
页数:6
相关论文
共 50 条
  • [21] Coverage of Transvenous Pulmonary Embolectomy - Medicare's Missed Opportunity for Evidence Generation
    Dhruva, Sanket S.
    Redberg, Rita F.
    NEW ENGLAND JOURNAL OF MEDICINE, 2022, 386 (10): : 904 - 906
  • [22] UNDERSTANDING STAKEHOLDER PERSPECTIVES ON MEDICARE'S COVERAGE WITH EVIDENCE DEVELOPMENT (CED) POLICY
    Gaffney, J.
    Liow, C.
    Walsh, E. M.
    Williams, R.
    VALUE IN HEALTH, 2014, 17 (03) : A11 - A11
  • [23] Representativeness of Studies Required Under Medicare's Coverage With Evidence Development Program
    Mooghali, Maryam
    Dhruva, Sanket S.
    Ross, Joseph S.
    Ramachandran, Reshma
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2024, 332 (22): : 1943 - 1945
  • [24] The Department of Justice Investigation and ICD Implantations Not Meeting Medicare's National Coverage Determination
    Desai, Nihar R.
    Parzynski, Craig
    Brindis, Ralph
    Spatz, Erica
    Masters, Claire
    Minges, Karl
    Peterson, Pamela
    Masoudi, Fred
    Oetgen, William
    Buxton, Alfred
    Zipes, Douglas
    Curtis, Jeptha
    CIRCULATION, 2017, 136
  • [25] Volume Considerations for Transcatheter Aortic Valve Replacement in Medicare's National Coverage Determination
    Sukul, Devraj
    Allen, Joseph
    Kumbhani, Dharam J.
    CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES, 2019, 12 (01): : e005216
  • [26] Medicare's coverage of colorectal cancer drugs: A case study in evidence development and policy
    Carino, Tanisha
    Williams, Reginald D., II
    Colbert, Allison M.
    Bridger, Perry
    HEALTH AFFAIRS, 2006, 25 (05) : 1231 - 1239
  • [27] REDEFINING "REASONABLE AND NECESSARY"? AN EMPIRICAL, COMPARATIVE ASSESSMENT OF MEDICARE'S COVERAGE WITH EVIDENCE DEVELOPMENT
    Chenoweth, M. D.
    Chambers, J. D.
    VALUE IN HEALTH, 2017, 20 (05) : A66 - A66
  • [28] The Use, Safety and Cost of Bariatric Surgery Before and After Medicare's National Coverage Decision
    Flum, David R.
    Kwon, Steve
    MacLeod, Kara
    Wang, Bruce
    Alfonso-Cristancho, Rafael
    Garrison, Louis P.
    Sullivan, Sean D.
    ANNALS OF SURGERY, 2011, 254 (06) : 860 - 865
  • [29] Association Between Medicare's National Coverage Determination and Utilization of Next-Generation Sequencing
    Sheinson, Daniel M.
    Wong, William B.
    Flores, Carlos
    Ogale, Sarika
    Gross, Cary P.
    JCO ONCOLOGY PRACTICE, 2021, 17 (11) : 687 - +
  • [30] Medicare's National Coverage Determination for Aducanumab - A One-Off or a Pragmatic Path Forward?
    Dhruva, Sanket S.
    Ramachandran, Reshma
    Ross, Joseph S.
    NEW ENGLAND JOURNAL OF MEDICINE, 2022, 387 (17): : 1539 - 1541